Switch from ARB Combination Tablets to Azilsartan: Clinical research on organ protective effect in hypertensive patients living in Okayama

Switch from ARB Combination Tablets to Azilsartan: Clinical research on organ protective effect in hypertensive patients living in Okayama - MAGENTA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012587

Enrollment

100

Registered

2013-12-16

Start date

2012-07-10

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1, Secondary hypertension 2, Severe hypertension(SBP 200mmHg or more or DBP 115mmHg or more) 3, Congestive heart failure 4, Severe valvular disease 5, Myocardial infarction or acute period of cerebrovascular disease(within 6 months) 6, Atrial fibrillation(paroxysmal,stained,chronic) 7, Malignant ventricular arrhythmia 8, Renal insufficiency(Serum creatinine 2mg/dL or more) 9, Severe Liver Dysfunction 10, Chronic inflammatory disease 11, The patient with a malignant tumor 12, Patients who are determined by the investigators to be unsuitable

Design outcomes

Primary

Measure	Time frame
Change in blood pressure	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesDepartment of C Department of Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026